Michael Benkowitz sold $640k of UTHR
PRESIDENT AND COO at UNITED THERAPEUTICS Corp. 2,000 shares at an average of $320.09, traded Mar 10, 2025, filed Mar 11, 2025.
Score components
- +20RolePresident
- +20Trade size$640k at market
- +20Share of holdings soldSold 100% of holdings
- +8Cluster2 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001562180-25-002291, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Mar 10, 2025 | MOption exercise Common Stockindirect: by Trust10b5-1 | +2,000 | $111.00 | $222k | 2,000 | Mar 11, 2025 |
| Mar 10, 2025 | SOpen-market sale Common Stockindirect: by Trust10b5-1 | -193 | $313.93 | $61k | 1,807 | Mar 11, 2025 |
| Mar 10, 2025 | SOpen-market sale Common Stockindirect: by Trust10b5-1 | -200 | $317.11 | $63k | 1,607 | Mar 11, 2025 |
| Mar 10, 2025 | SOpen-market sale Common Stockindirect: by Trust10b5-1 | -316 | $319.35 | $101k | 1,291 | Mar 11, 2025 |
| Mar 10, 2025 | SOpen-market sale Common Stockindirect: by Trust10b5-1 | -533 | $320.57 | $171k | 758 | Mar 11, 2025 |
| Mar 10, 2025 | SOpen-market sale Common Stockindirect: by Trust10b5-1 | -358 | $321.62 | $115k | 400 | Mar 11, 2025 |
| Mar 10, 2025 | SOpen-market sale Common Stockindirect: by Trust10b5-1 | -300 | $322.86 | $97k | 100 | Mar 11, 2025 |
| Mar 10, 2025 | SOpen-market sale Common Stockindirect: by Trust10b5-1 | -100 | $323.99 | $32k | 0 | Mar 11, 2025 |
| Mar 10, 2025 | MOption exercise Stock Optionsderivativeindirect: by Trust10b5-1 | -2,000 | $0.00 | $0 | 0 | Mar 11, 2025 |
Related signals
Other insiders at UNITED THERAPEUTICS Corp and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 23Weak | UNITED THERAPEUTICS Corp | Martine A Rothblatt Chairperson & CEO | $5.1M 9,500 shares | -3% | |
| 23Weak | UNITED THERAPEUTICS Corp | Martine A Rothblatt Chairperson & CEO | $5.2M 9,500 shares | -3% | |
| 23Weak | UNITED THERAPEUTICS Corp | Martine A Rothblatt Chairperson & CEO | $5.1M 9,500 shares | -3% | |
| 23Weak | UNITED THERAPEUTICS Corp | Martine A Rothblatt Chairperson & CEO | $5.1M 9,500 shares | -3% | |
| 23Weak | UNITED THERAPEUTICS Corp | Martine A Rothblatt Chairperson & CEO | $5.2M 9,500 shares | -3% | |
| 23Weak | UNITED THERAPEUTICS Corp | Martine A Rothblatt Chairperson & CEO | $5.5M 9,500 shares | -3% | |
| 18Weak | UNITED THERAPEUTICS Corp | Paul A Mahon EVP & GENERAL COUNSEL | $4.7M 8,300 shares | -16% | |
| 23Weak | UNITED THERAPEUTICS Corp | Martine A Rothblatt Chairperson & CEO | $3.9M 7,580 shares | -2% | |
| 38Weak | UNITED THERAPEUTICS Corp | Martine A Rothblatt Chairperson & CEO | $1.1M 1,920 shares | -1% | |
| 23Weak | UNITED THERAPEUTICS Corp | Martine A Rothblatt Chairperson & CEO | $4.5M 9,500 shares | -3% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.